American Chemical Society--235th National Meeting. Part 3.
Wyeth Research, CN 8000, Princeton, NJ 08543, USA. rotelld@wyeth.com
David
D
Rotella
D000818:Animals; D000930:Antidiarrheals / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000037:antagonists & inhibitors; D004345:Drug Industry; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism; D010600:Pharmacology / Q000639:trends*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors; D012106:Research; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
D000930:Antidiarrheals; D000970:Antineoplastic Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D009569:Nitric Oxide; D014568:Urokinase-Type Plasminogen Activator